Board of Directors

Walter Moos, Ph.D.

Moos_Photo_2015

Dr. Walter Moos retired as President of SRI Biosciences in early 2016 after more than a decade at the independent nonprofit. Prior to SRI, he served as Chairman/CEO of MitoKor (Migenix) and held positions of VP at Chiron (Novartis) and Warner-Lambert/Parke-Davis (Pfizer). Over his career, Dr. Moos and his teams have made significant contributions to all R&D phases, from early stage research on therapeutics and diagnostics to marketed pharmaceutical products. He has served on 20 business and scientific boards, not-for-profit and for-profit, including the Biotechnology Industry Organization (BIO), Circle, Critical Path Institute, Keystone Symposia, Oncologic (Aduro Biotech), Onyx Pharmaceuticals (Amgen) and Rigel Pharmaceuticals. He has advised and served as committee member for academic, government and investor groups, including University of Michigan, National Academy of Sciences, and Red Abbey Venture Partners.

Dr. Moos held faculty positions at major universities and has been an adjunct Professor at the University of California, San Francisco since 1992. He holds a Ph.D. in chemistry from the University of California, Berkeley and an a A.B. degree in chemistry and Harvard. He has co-founded several scientific journals, co-edited 6 books and has over 160 patents and publications.

Harold E. “Barry” Selick, Ph.D.

Dr. Harold E. “Barry” Selick has been the Chief Executive Officer of Threshold Pharmaceuticals since June 2002. From January 1999 to April 2002, he was Chief Executive Officer of Camitro Corporation, a biotechnology company. From 1992 to 1999, he was at Affymax Research Institute, the drug discovery technology development center for Glaxo Wellcome plc, most recently as Vice President of Research. Prior to working at Affymax he held scientific positions at Protein Design Labs, Inc. and Anergen, Inc. As a staff scientist at Protein Design Labs, he co-invented the technology underlying the creation of fully humanized antibody therapeutics and applied that to PDL’s first product, Zenapax, which was developed and commercialized by Roche for the prevention of kidney transplant rejection. Dr. Selick received his B.S. and Ph.D. degrees from the University of Pennsylvania and was a Damon Runyon-Walter Winchell Cancer Fund Fellow and an American Cancer Society Senior Fellow at the University of California, San Francisco.

Selick headshot June 2014

Volker Schellenberger, Ph.D., CEO

Volker

Dr. Volker Schellenberger is a co-founder of Amunix and currently serves as President and CEO. Dr. Schellenberger has extensive industry experience in protein engineering and drug discovery. Previously, he headed the Protein Engineering department at Genencor, where he invented combinatorial consensus mutagenesis, selection by micro-compartmentalization, as well as mutator technology. In addition, he initiated and led collaborations with Seattle Genetics that focused on antibody-enzyme fusion proteins. Prior to his work on biotherapeutics, Dr. Schellenberger directed projects optimizing enzymes for industrial applications as well as microbes for metabolic pathway engineering.

Dr. Schellenberger received his Ph.D. from Leipzig University, where he studied protease catalyzed peptide synthesis. After postdoctoral studies at the Institute for Protein Research in Pushchino (Russia), he moved to the University of Göttingen where he developed a novel method for the production of peptides from recombinant peptide-multimers. After a postdoctoral fellowship with Bill Rutter at the University of California, San Francisco, Dr. Schellenberger joined Genencor in 1994. Dr. Schellenberger is the author of over 40 scientific papers and an inventor on more than 70 issued and pending patent applications. He is also the recipient of the Karl Lohman award of the German Society of Biochemists.